Grant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of the stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $66.93, for a total transaction of $1,003,950.00. Following the completion of the sale, the chief executive officer now directly owns 477,847 shares in the company, valued at $31,982,299.71. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total value of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.91, for a total value of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The shares were sold at an average price of $66.03, for a total value of $1,980,900.00.
• On Tuesday, January 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.92, for a total transaction of $958,800.00.
• On Tuesday, January 2nd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $63.89, for a total transaction of $167,136.24.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $68.50 on Thursday. The company’s 50-day moving average price is $71.06 and its 200-day moving average price is $59.49. Vaxcyte, Inc. has a twelve month low of $34.11 and a twelve month high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period in the previous year, the business earned ($0.73) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Institutional Investors Weigh In On Vaxcyte

Several large investors have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Vaxcyte by 39.0% during the 2nd quarter. BlackRock Inc. now owns 7,065,088 shares of the company’s stock worth $352,830,000 after acquiring an additional 1,983,223 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Vaxcyte by 2,164.2% during the second quarter. Alliancebernstein L.P. now owns 1,888,106 shares of the company’s stock worth $94,292,000 after purchasing an additional 1,804,718 shares in the last quarter. Westfield Capital Management Co. LP purchased a new stake in shares of Vaxcyte in the 3rd quarter valued at about $51,180,000. Norges Bank acquired a new stake in shares of Vaxcyte in the 4th quarter valued at about $57,494,000. Finally, Fred Alger Management LLC acquired a new position in Vaxcyte during the fourth quarter worth approximately $42,066,000. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of analyst reports. Needham & Company LLC upped their price objective on Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Bank of America boosted their price target on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 2nd. Finally, Mizuho began coverage on shares of Vaxcyte in a research note on Thursday, December 7th. They set a “buy” rating and a $69.00 price target on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and an average price target of $78.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.